Can imipramine be combined with a low-dose Remeron (mirtazapine)?

Can You Take Imipramine with Low-Dose Remeron (Mirtazapine)?

Yes, imipramine can be combined with low-dose mirtazapine, though this combination requires careful monitoring and is not typically a first-line approach. The combination has been studied and used clinically, but carries specific risks that must be weighed against potential benefits.

Evidence for the Combination

The combination of tricyclic antidepressants (TCAs) like imipramine with mirtazapine has documented clinical use. A direct comparison study found that when lithium was added to either imipramine or mirtazapine for treatment-resistant depression, the imipramine strategy showed superior efficacy (64% response vs 48% with mirtazapine), though imipramine caused more serious side effects leading to discontinuation in 5 patients 1. Importantly, no serious adverse effects were observed when lithium was added to either medication, suggesting the drugs can be combined with other agents 1.

Guidelines acknowledge that combining antidepressants from different classes may offer therapeutic advantages for treatment-resistant cases. The insomnia guidelines specifically list both mirtazapine and tricyclics (including amitriptyline, doxepin) as sedating antidepressants that can be combined with other agents 2. Cancer pain guidelines note that tricyclics like imipramine can be used as coanalgesics, recognizing their anticholinergic effects 3.

Critical Safety Considerations

Serotonin Syndrome Risk

The primary concern is serotonin syndrome, which occurs in 14-16% of SSRI overdoses and can result from combining serotonergic medications 4. While mirtazapine has a unique mechanism (α2-antagonist enhancing norepinephrine and serotonin), and imipramine affects multiple neurotransmitter systems, the combination increases serotonergic activity. Monitor for: tremor, diarrhea, delirium, neuromuscular rigidity, and hyperthermia.

Additive Side Effects

Both medications share overlapping adverse effect profiles:

• Anticholinergic effects: Imipramine (a tertiary amine TCA) has significant anticholinergic properties including sedation, dry mouth, and urinary hesitancy 3. Mirtazapine also has anticholinergic activity 5.
• Sedation: Both are highly sedating, which compounds when combined
• Orthostatic hypotension: Both medications can cause this, particularly problematic in elderly patients
• Weight gain: Mirtazapine notably causes weight gain (49% of pediatric patients gained ≥7% body weight) 5
• Cardiac effects: TCAs impair cardiac conduction; mirtazapine can prolong QTc interval 6, 5

Special Population Concerns

Elderly patients face heightened risks. Both drugs have decreased clearance in older adults 5. The combination of sedation, anticholinergic effects, and orthostatic hypotension significantly increases fall risk and confusion 7, 5. If this combination is necessary in elderly patients, start with the lowest possible doses and monitor closely for over-sedation and confusion.

Renal/hepatic impairment requires dose reduction for both medications, as mirtazapine clearance is reduced in moderate-to-severe impairment 5.

Clinical Algorithm for Use

When to Consider:

1. Treatment-resistant depression after adequate trials of monotherapy
2. Specific symptom profiles requiring both noradrenergic enhancement and sedation
3. Neuropathic pain with comorbid depression and insomnia

How to Implement:

1. Start low: Begin with imipramine 10-25 mg nightly and mirtazapine 7.5 mg nightly
2. Titrate slowly: Increase imipramine by 10-25 mg every 5-7 days; mirtazapine can be increased to 15 mg after 2 weeks if needed 3, 5
3. Monitor closely: Weekly assessment initially for sedation, orthostatic hypotension, anticholinergic effects, and serotonin syndrome symptoms
4. Consider alternatives first: Secondary amine TCAs (nortriptyline, desipramine) are better tolerated than imipramine and may be safer choices if a TCA is needed 3, 8

Preferred Alternatives

Rather than combining imipramine with mirtazapine, consider:

• Mirtazapine combined with an SSRI or SNRI (more commonly studied, though a large trial showed minimal benefit) 9
• Switching from imipramine to a better-tolerated antidepressant if side effects are prohibitive 1
• Using nortriptyline or desipramine instead of imipramine if a TCA is required, as these secondary amines have fewer anticholinergic effects 3, 8

Bottom Line

While the combination is pharmacologically feasible and has been used clinically, it should be reserved for treatment-resistant cases where monotherapy has failed, and only after careful risk-benefit assessment. The overlapping side effect profiles—particularly sedation, anticholinergic effects, and cardiovascular risks—require vigilant monitoring. In elderly patients or those with cardiac disease, this combination carries substantial risk and alternative strategies should be strongly considered.